Completed an IPO on December 17, 2020, raising approximately USD 130 million and listing on NASDAQ under ticker MASS.

Reported 2023 revenue of about USD 50.23 million with EBITDA of USD -40.37 million, indicating meaningful commercial traction but ongoing investment mode and lack of profitability.

Offers a portfolio of field-deployable chemical analysis products including MX908 variants, ProtectIR, VipIR, XplorIR, and ThreatID for CBRN, hazmat, border security, and law-enforcement use cases.

Acquired NIRLAB AG in Lausanne, Switzerland to add AI-powered, cloud-connected near‑infrared narcotics analysis to its handheld chemical analysis capabilities.

Actively recruiting a Director of Investor Relations to build a best‑in‑class IR program and enhance communication with the investment community.

Hiring a Product Line Manager/Technical Sales Specialist for the Czitek FTIR product line, with responsibilities spanning product positioning, digital marketing, and global reseller support.

Operating with a corporate office in Burlington, MA, a manufacturing center in Danbury, CT, and a growing remote workforce worldwide, indicating distributed operational expansion.

Positions itself publicly as a trailblazing culture of technology innovators and serial entrepreneurs aiming to revolutionize chemical and biochemical analysis, suggesting strong internal innovation and mission orientation.